Furthermore, analyses with TCGA database also revealed that, among the 28 cancer types investigated, both PRDX1 and PRDX2 proteins exhibited the most significant differential expression levels in DLBCL tumor (Fig. 1E, F), suggesting important roles of these two proteins in the development of DLBCL, and by that, the potential therapeutic targets of ART and other drugs. The gene discussed is PRDX2; the disease is diffuse large B-cell lymphoma.